These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1545388)

  • 1. Colchicine-specific Fab fragments alter colchicine disposition in rabbits.
    Sabouraud AE; Urtizberea M; Cano NJ; Grandgeorge M; Rouzioux JM; Scherrmann JM
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1214-9. PubMed ID: 1545388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments.
    Ochs HR; Smith TW
    J Clin Invest; 1977 Dec; 60(6):1303-13. PubMed ID: 914999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs.
    Owens SM; Mayersohn M
    Drug Metab Dispos; 1986; 14(1):52-8. PubMed ID: 2868866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of colchicine-specific Fab fragments on the hepatic clearance of colchicine.
    Sabouraud A; Redureau M; Gires P; Martinet M; Scherrmann JM
    Drug Metab Dispos; 1993; 21(6):997-1002. PubMed ID: 7905405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon.
    Smith TW; Lloyd BL; Spicer N; Haber E
    Clin Exp Immunol; 1979 Jun; 36(3):384-96. PubMed ID: 114346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fab-bound colchicine appears to adopt Fab fragment disposition in rats.
    Sabouraud AE; Urtizberea M; Benmoussa K; Cano NJ; Scherrmann JM
    J Pharm Pharmacol; 1992 Dec; 44(12):1015-9. PubMed ID: 1361548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of specific antibody Fab fragments on desipramine pharmacokinetics in the rat in vivo and in the isolated, perfused liver.
    Keyler DE; Le Couteur DG; Pond SM; St Peter JV; Pentel PR
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1117-23. PubMed ID: 7891324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats.
    Valentine JL; Arnold LW; Owens SM
    J Pharmacol Exp Ther; 1994 Jun; 269(3):1079-85. PubMed ID: 8014850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunopharmacological activity of monoclonal antidigitoxin.
    Urtizberea M; Latour M; Edelman L; Carcagne J; Armand J; Scherrmann JM
    Dev Biol Stand; 1990; 71():147-57. PubMed ID: 2401380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colchicine disposition in patients with familial Mediterranean fever with renal impairment.
    Ben-Chetrit E; Scherrmann JM; Zylber-Katz E; Levy M
    J Rheumatol; 1994 Apr; 21(4):710-3. PubMed ID: 8035398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and Fab fragments in rat.
    Hong G; Bazin-Redureau MI; Scherrmann JM
    J Pharm Sci; 1999 Jan; 88(1):147-53. PubMed ID: 9874717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of colchicine: a review of experimental and clinical data.
    Sabouraud A; Rochdi M; Urtizberea M; Christen MO; Achtert G; Scherrmann JM
    Z Gastroenterol; 1992 Mar; 30 Suppl 1():35-9. PubMed ID: 1449014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats.
    Bittner B; González RC; Walter I; Kapps M; Huwyler J
    Biopharm Drug Dispos; 2003 May; 24(4):173-81. PubMed ID: 12698501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats.
    McClurkan MB; Valentine JL; Arnold L; Owens SM
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1439-45. PubMed ID: 8371148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent reversal of acute murine colchicine poisoning by goat colchicine-specific Fab fragments.
    Sabouraud A; Urtizberea M; Grandgeorge M; Gattel P; Makula ME; Scherrmann JM
    Toxicology; 1991; 68(2):121-32. PubMed ID: 1891780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efflux of intracellular colchicine in lymphocytes with colchicine-specific Fab fragments.
    Chappey ON; Niel E; Debray M; Wautier JL; Scherrmann JM
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1072-6. PubMed ID: 7562471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats.
    Valentine JL; Owens SM
    J Pharmacol Exp Ther; 1996 Aug; 278(2):717-24. PubMed ID: 8768723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice.
    Covell DG; Barbet J; Holton OD; Black CD; Parker RJ; Weinstein JN
    Cancer Res; 1986 Aug; 46(8):3969-78. PubMed ID: 3731067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab.
    Grene-Lerouge NA; Bazin-Redureau MI; Debray M; Scherrmann JM
    Toxicol Appl Pharmacol; 1996 May; 138(1):84-9. PubMed ID: 8658517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.